As part of the journal’s “Innovations in wound care” section, the latest edition features a guest editorial by our CEO Daniela Marino and CIO Vincent Ronfard.
When patients suffer from large and severe skin injuries affecting more than 50% of the body, such as burns, then the current standard of care – autografting – presents real challenges.
New approaches to bioengineering skin could change the paradigm for large burn treatment. But even so, other challenges remain, such as mainly manual, time-consuming and costly production.
Our authors put forward that automation is the answer, meeting three key objectives: reduction in manufacturing time, improved skin graft quality and safety, and decreased costs.
CUTISS has developed the denovoSkin, an autologous bioengineered dermo-epidermal skin graft, intended to provide permanent skin coverage with minimal scarring. It is currently in phase II clinical trials, and is manufactured manually in a fully equipped cleanroom by highly skilled personnel.
The future of denovoSkin is the automation of its manufacturing process, and CUTISS has already produced groundbreaking research and development grade prototypes for the automated production of denovoSkin.
At this moment, CUTISS remains the industry pioneer in the automation of bioengineered skin manufacturing.
Read the ARTICLE for further insights on the challenges and opportunities in regenerative medicine.
